E. Edwards, L. Bennett, and J. Cecka, Effect of HLA matching on the relative risk of mortality for kidney recipients : a comparison of the mortality risk after transplant to the mortality risk of remaining on the waiting list, Clin Transplant, vol.64, issue.9, pp.1274-1277, 1997.

A. Matas, K. Gillingham, W. Payne, and J. Najarian, The impact of an acute rejection episode on long-term renal allograft survival

E. Thervet, J. Zuber, and R. Sberro, Immunosuppressive treatments: Mechanisms of action and clinical use, Nephrol ther, issue.7, pp.566-81, 2007.

J. Mayes, J. Thistlethwaite, J. Stuart, M. Buckingham, and F. Stuart, Reexposure to OKT3 in renal allograft recipients, Transplantation, vol.45, pp.349-53, 1988.

J. Bourdage and D. Hamlin, Comparative antithymocyte globulin and antilymphocyte/antilymphoblast globulin anti-CD antigen analysis by flow cytometry, Transplantation, vol.59, pp.1194-1200, 1995.

K. Budde, P. Glander, and B. Krämer, Conversion from mycophenolate mofetil to enteric coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus : clinical, pharmacokinetic, and pharmacodynamic outcomes, Transplantation, vol.83, pp.417-424, 2007.

G. Stallone, A. Schena, and B. Infante, Sirolimus for kaposi's sarcoma in renal transplant recipients, N Engl J Med, vol.352, pp.1317-1340, 2005.

B. Kahan, R. Wong, and C. Carter, A phase I study of a 4 week-course of SDZ-RAD (RAD) quiescent ciclosporine-prednisone-treated renal transplant recipients, Transplantation, vol.68, pp.1100-1106, 1999.

C. Johnson, N. Ahsan, and T. Gonwa, Randomized trial of tacrolimus(prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation, Transplantation, vol.69, issue.5, pp.834-875, 2000.

N. Ahsan, C. Johnson, and T. Gonwa, Randomized trial of tacrolimus plus mycophenolate mofetil or azathioprine versus cyclosporine oral solution plus mycophenolate mofetil after cadaveric kidney transplantation : results at 2 years, Transplantation, vol.72, issue.2, pp.245-50, 2001.

J. Grinyó, H. Ekberg, R. Mamelok, F. Oppenheimer, J. Sánchez-plumed et al., The pharmacokinetics of mycophenolate mofetil in renal transplant recipients receiving standard-dose or low-dose cyclosporine, low-dose tacrolimus or low-dose sirolimus: the Symphony pharmacokinetic substudy, Nephrol Dial Transplant, vol.24, issue.7, pp.2269-76, 2009.

S. Cremers, R. S. Hartigh, and J. König-quartel-eric-van-kan, Characterizing the role of enterohepatic recycling in the interactions between mycophenolate mofetil and calcineurin inhibitors in renal transplant patients by pharmacokinetic modelling, British Journal of Clinical Pharmacology, vol.60, issue.3, pp.249-256, 2005.

H. Silva, J. Yang, H. Abouljoud, and M. , One-year results with extended-release Tacrolimus/MMF, Tacrolimus/MMF and cyclosporine/MMF in de novo kidney transplant recipients, Am J Transplant, vol.7, issue.3, pp.595-608, 2007.

H. Ekberg, H. Tedesco-silva, and A. Demirbas, Reduced exposure to calcineurin inhibitors in renal transplantation, N Engl J Med, vol.357, issue.25, pp.2562-75, 2007.

H. Ekberg, C. Bernasconi, and H. Tedesco-silva, Calcineurin inhibitor minimization in the Symphony study : observational results 3 years after transplantation, Am J Transplant, vol.9, issue.8, pp.1876-85, 2009.

J. Squifflet, L. Backman, K. Claesson, K. Dietl, H. Ekberg et al., Dose optimization of mycophenolate mofetil when administered with a low dose of tacrolimus in cadaveric renal transplant recipients, Transplantation Jul, vol.15, issue.721, pp.63-69, 2001.

H. Kocak, U. Yacupoglu, and G. Karatas, Tacrolimus plus low dose mycophenolate mofetil in renal transplant recipients : better 2 year graft and patient survival than with a higher mycophenolate mofetil dose, Transplant Proc, vol.37, issue.7, pp.3009-3011, 2005.

B. Kiberd, J. Puthenparumpil, A. Fraser, S. Tett, and J. Lawen, Impact of Mycophenolate Mofetil Loading on Drug Exposure in the Early Posttransplant Period, Transplantation Proceedings, vol.37, pp.2320-2323, 2005.

J. Gozdowska, A. Urbanowicz, T. Baczkowska, J. Pazik, and B. Matlosz, Safety and tolerance of sodium mycophenolate in patients after renal transplantation-an observational study, Transplantation Proceedings, vol.41, pp.3016-3034, 2009.

T. Rath and M. Küpper, Comparison of inosine-monophosphate-dehydrogenase activity in patients with enteric-coated mycophenolate sodium or mycophenolate mofetil after renal transplantation. Transplant, pp.2524-2532, 2009.

Z. Wlodarczyck, J. Walaszewski, and F. Perner, Steroid withdrawal at 3 months after kidney transplantation: a comparison of two tacrolimus based regimens. Transplant Int, Feb, vol.18, issue.2, pp.157-162, 2005.

D. Kuypers, P. Evenepoel, B. Maes, W. Coosemans, J. Pirenne et al., The use of an anti-CD25 monoclonal antibody and mycophenolate mofetil enables the use of a low dose tacrolimus and early withdrawal of steroids in renal transplant recipients, Clin Transplant, vol.17, issue.3, pp.234-241, 2003.

Y. Vanrenterghem, V. Hoof, J. Squifflet, and J. , Minimization of immunosuppressive therapy after renal transplantation : results of randomized controlled trial, Am J Transplant, vol.5, issue.1, pp.87-95, 2005.

L. Rostaing, D. Cantarovich, and G. Mourad, Corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil and daclizumab induction in renal transplantation, Transplantation, vol.79, issue.7, pp.807-821, 2005.

S. Vitko, M. Klinger, and K. Salmela, Two corticosteroid-free regimens-tacrolimus monotherapy after basiliximab administration and tacrolimus/ mycophenolate mofetil-in comparison with a standard triple regimen in renal transplantation : results of the Atlas study. Transplantation, pp.1734-1775, 2005.

B. Kramer, M. Klinger, and Z. Wlodarczyck, Tacrolimus combined with two different corticosteroid-free regimens compared with a standard triple regimen in renal transplantation : one year observational results, Clin Transplant, vol.24, issue.1, pp.1-9, 2010.

N. Undre, P. Stevenson, and A. Schäfer, Pharmacokinetics of Tacrolimus : Clinical Relevant Aspects, Transplantation Proceeding, vol.31, pp.21-24, 1999.

A. Jain, K. Abu-elmagd, and H. Abdallah, Pharmacokinetics of FK 506 in Liver Recipients after Continuous Intravenous Infusion, J Clin Pharmacol, vol.33, issue.7, pp.606-617, 1993.

K. Sewing, Pharmacokinetics, dosing principles, and blood level monitoring of FK 506, Transplant Proc, vol.26, issue.6, pp.3267-3276, 1994.

D. Peters, A. Fitton, G. Plosker, and F. D. Tacrolimus, A review of its pharmacology and therapeutic potential in hepatic and renal transplantation, Drugs, vol.46, pp.746-794, 1993.

U. Christians, Measurment of FK 506 by HPLC and Isolation and Characterization of Its Metabolites, Transplantation Proceedings, vol.23, issue.1, pp.940-941, 1991.

A. Trull, Therapeutic monitoring of tacrolimus, Ann Clin Biochem, vol.35, pp.167-180, 1998.

T. Saeki, K. Ueda, Y. Tanigawara, R. Hori, and T. Komano, Human P-glycoprotein transports cyclosporin A and FK 506, J Biol Chem, vol.268, pp.6077-6080, 1993.

R. Press, B. Ploeger, and J. Den-hartgh, Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipients, Ther Drug Monit, vol.31, issue.2, pp.187-97, 2009.

A. Barry and M. Levine, A systematic review of the effect of CYP3A5 genotype on the apparent oral clearance of tacrolimus in renal transplant recipients, Ther Drug Monit, vol.32, issue.6, pp.718-732, 2010.

A. Robert, H. Maarteen, . Ml-stolk, and . Leo, Tacrolimus pharmacokinetics and pharmacogenetics : influence of adenosine triphosphate-binding cassette B1 (ABCB1) and cytochrome (CYP) 3A polymorphisms, Fundamental &Clinical Pharmacology, vol.21, pp.427-435, 2007.

P. Kuehl, J. Zhang, and Y. Lin, Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression, Nat genet, vol.27, pp.383-91, 2001.

V. Haufroid, P. Wallemacq, and V. Vankerckhove, CYP3A5 and ABCB1 polymorphisms and tacrolimus pharmacokinetics in renal transplant candidates : guidelines from an experimental study, Am J Transplant, vol.6, pp.2706-2719, 2006.

T. Gelder and D. Hesselink, Dosing tacrolimus based on CYP3A5 genotype : will it improve clinical outcome ?, Clinical phamacol ther, vol.87, issue.6, pp.640-641, 2010.

E. Scholten, S. Cremers, and R. Schoemaker, AUC-guided dosing of tacrolimus prevents progressive systemic overexposure in renal transplant recipients, Kidney int, vol.67, pp.2440-2447, 2005.

Y. Böttiger, C. Brattström, G. Tyden, J. Säwe, and C. Groth, Tacrolimus whole blood concentrations correlate closely to side effects in renal transplant recipients, J Clin pharmacol, vol.48, pp.445-448, 1999.

P. Salm, P. Taylor, and A. Clark, High-performance liquid chromatography-tandem mass spectrometry as a reference for analysis of tacrolimus to assess two immunoassays in patients with live rand renal transplants, Ther Drug Monit, vol.19, issue.6, pp.694-700, 1997.

J. Schiff, E. Cole, and M. Cantarovich, Therapeutic Monitoring of Calcineurin Inhibitors for the Nephrologist, Clin J Am Soc Nephrol, vol.2, pp.374-384, 2007.

K. Solez, F. Vincenti, and R. Filo, Histopathologic findings from 2-year protocol biopsies from a U.S. multicenter kidney transplant trial comparing tacrolimus versus cyclosporine : a report of the FK506 Kidney Transplant Study Group, Transplantation, vol.66, issue.12, pp.1736-1776, 1998.

A. Mueller, K. Platz, and W. Bechstein, Neurotoxicity after orthotopic liver transplantation, Transplantation, vol.58, issue.2, pp.155-69, 1994.
DOI : 10.1097/00007890-199405820-00006

M. Weir and J. Fink, Risk for postransplant diabetes mellitus with current immunosuppressive medications, Am J Kidney Dis, vol.34, issue.1, pp.1-13, 1999.

T. Mc-cune, L. Thacker, . Ii, and T. Peters, Effects of tacrolimus on hyperlipidemia after successful renal transplantation: a Southeastern Organ Procurement Foundation multicenter clinical study, Transplantation, vol.65, issue.1, pp.87-92, 1998.

T. Ochiai, K. Fukao, and K. Takahashi, Phase III study of FK 506 in kidney transplantation, Transplant Proc, vol.27, issue.1, pp.829-862, 1995.

A. Fisher, E. Mor, and P. Hytiroglou, FK 506 hepatotoxicity in liver allograft recipients, Transplantation, vol.59, issue.11, pp.1631-1633, 1995.

R. Wolfe, V. Ashby, and E. Milford, Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant, N Engl J Med, vol.341, pp.1725-1755, 1999.

B. Kasiske, C. Guijarro, Z. Massy, M. Wiederkerhr, and J. Ma, Cardiovascular disease after renal transplantation, J Am Soc Nephrol, vol.7, pp.158-65, 1996.

S. Seigneux and K. Hadaya, Prise en charge médicale des patients greffés rénaux au-delà de la première année post-transplantation, 2008.

A. Mayer, J. Dmitrewski, and J. Squifflet, Multicenter randomized trial comparing tacrolimus (FK506) and ciclosporine in the prevention of renal allograft rejection, a report of the European tacrolimus Multicenter Renal Study Group, Transplantation, vol.64, pp.436-443, 1997.

G. Ligtenberg, R. Hene, and P. Blankestijn, Tacrolimus versus ciclosporine : a favorable vascular risk profile in renal transplant recipients, J Am Soc Nephrol, vol.10, p.736, 1999.

C. Staatz, C. Willis, P. Taylor, and S. Tett, Population pharmacokinetics of tacrolimus in adult kidney transplant recipients, Clin Pharmacol Ther, vol.72, issue.6, pp.660-669, 2002.

C. Manzanares, Suivi thérapeutique pharmacologique du tacrolimus : une notion qui change, Therapie, vol.57, issue.2, pp.133-136, 2002.

C. Lenneart, J. I. Borra, . Roodnat, J. Kal, R. Mathot et al., High within-patient variability in the clearance of tacrolimus is a risk factor for poor long-term outcome after kidney transplantation, Nephrol Dial Transplant, vol.25, pp.2757-2763, 2010.

W. Bennett, A. Demattos, M. Meyer, T. Andoh, and J. Barry, Chronic cyclosporine nephropathy : the Achilles'heel of immunosuppressive therapy, Kidney Int, vol.50, pp.1089-100, 1996.

S. Leroy, A. Isapof, and M. Fargues, Tacrolimus nephrotoxicity : beware of the association of diarrhea, drug interaction and pharmacogenetics, Pediatr Nephrol, 2010.

S. Fu, Y. Wang, L. Yu, Q. Li, Y. Wang et al., Factors responsible for interindividual variations in dosage/concentration of tacrolimus in renal transplant recipients, Nan Fang Yi Ke Da Xue Xue Bao, vol.28, issue.12, pp.2161-2165, 2008.

K. Takahashi, I. Yano, and Y. Fukuhara, Distinct effects of omeprazole and rabeprazole on the tacrolimus blood concentration in a kidney transplant recipient, Drug Metab.Pharmacokinet, vol.22, issue.6, pp.441-444, 2007.

S. Shishido, H. Asanuma, and H. Nakai, The impact of repeated subclinical acute rejection on the progression of chronic allograft nephropathy, J Am Soc Nephrol, vol.14, pp.1046-52, 2003.

G. Basadonna, . Matasaj, and K. Gillingham, Early versus late acute renal allograft rejection: impact on chronic rejection, Transplantation, vol.55, issue.5, pp.993-998, 1993.

M. Vicari-christensen, S. Repper, S. Basile, and Y. Danella, Tacrolimus : review of pharmacokinetics, pharmacodynamics, and pharmacogenetics to facilitate prationners'understanding and offer strategies foe educating patients and promoting adherence, Prog Transplant Sept, vol.19, issue.3, pp.277-84, 2009.